Comparative Pharmacology
Head-to-head clinical analysis: SULFAIR 15 versus SULFALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFAIR 15 versus SULFALAR.
SULFAIR-15 vs SULFALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfadoxine is a long-acting sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. Pyrimethamine inhibits dihydrofolate reductase, synergistically inhibiting nucleic acid synthesis in Plasmodium species.
Sulfamethoxazole is a sulfonamide that competitively inhibits dihydropteroate synthase, blocking folic acid synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism in bacteria.
15 mg orally every 6 hours, not to exceed 60 mg/day.
Oral: 500 mg to 1 g every 12 hours; extended-release: 1 g every 12 hours. Intravenous: 1 g every 12 hours.
None Documented
None Documented
12–15 hours in healthy adults; prolonged to 20–30 hours in moderate hepatic impairment.
Terminal elimination half-life: 7-12 hours (prolonged in renal impairment up to 24-48 hours; clinical context: dosing interval adjustment needed for CrCl <30 mL/min)
Renal excretion unchanged: 70%; hepatic metabolism to inactive metabolites: 20%; fecal excretion: 10%.
Renal: approximately 70-80% as unchanged drug and acetylated metabolite; biliary/fecal: 20-30%
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)